Breaking News

Galderma Granted Manufacturing License Updates for New Biologics Capabilities

Establishes the Uppsala site as a world-class center of excellence for dermatology products.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Galderma recently announced that the Swedish Medical Products Agency (Läkemedelsverket) issued key manufacturing license updates that will allow the company to pursue its growth and innovation roadmap. The license updates issued following the agency’s good manufacturing practices (GMP) inspection of Galderma’s center of excellence in Uppsala, Sweden, enable Galderma to manufacture and perform bioanalytical testing on RelabotulinumtoxinA (QM1114). One of Galderma’s key innovation pipeline ass...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters